Education
About Us
Working with TipRanks
Follow Us
Zura Bio (ZURA)
NASDAQ:ZURA
ZURA Stock Chart & Stats
$6.69
-$0.21(-8.71%)
At close: 4:00 PM EST
$6.69
-$0.21(-8.71%)
Day’s Range― - ―
52-Week Range$0.97 - $6.88
Previous CloseN/A
Volume136.30K
Average Volume (3M)635.94K
Market Cap
$435.01M
Enterprise Value$295.99M
Total Cash (Recent Filing)$139.02M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Apr 01, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding65,023,310
10 Day Avg. Volume293,319
30 Day Avg. Volume635,938
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.28
Price to Sales (P/S)0.00
P/FCF Ratio-6.67
Enterprise Value/Market Cap0.68
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-11.84K
Enterprise Value/Ebitda-4.29
Forecast
1Y Price Target
$19.67Price Target Upside194.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.84
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Advanced Bispecific PipelineA differentiated dual-pathway bispecific (tibulizumab) with Phase 2 studies and slated readouts provides structural de-risking potential. Successful clinical data would materially strengthen the company’s long-term commercial prospects and redress the typical binary risk of single-pathway biologics.
Near-term Funding Runway To Key MilestonesA disclosed cash position and runway through 2027 meaningfully reduce near-term dilution risk and enable the company to fund pivotal data generation. This allows management to focus on clinical execution and readouts rather than immediate financing, improving the odds of reaching value-creating milestones.
Low Financial LeverageZero reported debt and positive equity provide structural flexibility: lower interest burden, fewer covenant constraints, and clearer options for raising capital (equity, partnerships). This balance-sheet profile supports ongoing R&D spending without immediate interest expense pressure.
Bears Say
Pre-revenue, Widening LossesThe company remains pre-revenue with materially negative net income, meaning profitability is contingent on clinical success and eventual commercialization. This structural unprofitability elevates dilution risk and makes long-term shareholder value highly dependent on trial outcomes rather than operating leverage.
Persistent High Cash BurnSustained negative operating and free cash flows indicate the business is not self-funding and will likely need external capital before commercialization. Continued burn erodes equity, constrains optionality for expanding programs, and raises the probability of financing-driven dilution or deal-making on unfavorable terms.
Governance And Leadership TurnoverRecent CEO change, a director resignation, and a board-led internal review that reset agreements signify governance disruption. Such structural leadership shifts can slow strategic execution, introduce direction changes, and create uncertainty for partners and investors during a period when consistent clinical development execution is critical.
Zura Bio News
ZURA FAQ
What was Zura Bio’s price range in the past 12 months?
Zura Bio lowest stock price was $0.97 and its highest was $6.88 in the past 12 months.
What is Zura Bio’s market cap?
Zura Bio’s market cap is $435.01M.
When is Zura Bio’s upcoming earnings report date?
Zura Bio’s upcoming earnings report date is Apr 01, 2026 which is in 34 days.
How were Zura Bio’s earnings last quarter?
Zura Bio released its earnings results on Nov 13, 2025. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.191 by -$0.019.
Is Zura Bio overvalued?
According to Wall Street analysts Zura Bio’s price is currently Undervalued.
Does Zura Bio pay dividends?
Zura Bio does not currently pay dividends.
What is Zura Bio’s EPS estimate?
Zura Bio’s EPS estimate is -0.2.
How many shares outstanding does Zura Bio have?
Zura Bio has 65,023,310 shares outstanding.
What happened to Zura Bio’s price movement after its last earnings report?
Zura Bio reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.191. Following the earnings report the stock price went down -9.719%.
Which hedge fund is a major shareholder of Zura Bio?
Currently, no hedge funds are holding shares in ZURA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zura Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.67 (194.02% Upside)
$19.67 (194.02% Upside)
Blogger Sentiment
Bullish
ZURA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▲ 45.9%
Last 30 Days ▲ 45.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
366.42%
12-Months-Change
Fundamentals
Return on Equity
-47.85%
Trailing 12-Months
Asset Growth
-23.87%
Trailing 12-Months
Company Description
Zura Bio
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
ZURA Stock 12 Month Forecast
Average Price Target
$19.67
▲(194.02% Upside)
Technical Analysis
Ownership Overview
7.69%
Insiders
2.11% Mutual Funds
9.64% Other Institutional Investors
79.67% Public Companies and
Individual Investors